Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001172661-25-003249·Enliven Therapeutics, Inc.
Schedule 13G ownership disclosure
Enliven Therapeutics Inc
Common Stock, $0.001 par value per share · CUSIP: 29337E102
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Polar Capital Holdings Plc
Shares: 2,536,881.00 · Class: 5.17%
- Polar Capital LLP
Shares: 2,536,881.00 · Class: 5.17%
- Polar Capital Funds PLC - Biotechnology Fund
Shares: 2,536,881.00 · Class: 5.17%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001172661-25-003249
- Form type
- SCHEDULE 13G
- Filer
- Enliven Therapeutics, Inc.
- CIK
- CIK 1672619
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership